Prolor Biotech Climbs Most in Two Weeks on Trial Update

Prolor Biotech Inc. gained the most in two weeks after results from an extended Phase II trial of hGH-CTP human growth hormone showed a single weekly treatment may replace daily injections and was safe.

The shares jumped 3.8 percent, the most since April 22, to 20.89 shekels at the 4:30 p.m. close in Tel Aviv.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE